MAP7 promotes proliferation and migration of breast cancer cells and reduces the sensitivity of breast cancer cells to paclitaxel

Reference

• Bloom JR, Stewart SL, Johnston M, et al. Sources of support and the physical and mental well-being of young women with breast cancer. Soc Sci Med. 2001;53(11):1513–1524.
   PubMed Web of Science ®Google Scholar
• Kim Y, Yoo K-Y, Goodman MT. Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing factors. Asian Pac J Cancer Prev. 2015;16(7):2857–2870.
   PubMedGoogle Scholar
• Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004;9(4):361–377.
   PubMed Web of Science ®Google Scholar
• Videira M, Reis RL, Brito MA. Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochim Biophys Acta. 2014;1846(2):312–325.
   PubMed Web of Science ®Google Scholar
• Scully OJ, Bay B-H, Yip G, et al. Breast cancer metastasis. Cancer Genom Proteom. 2012;9(5):311–320.
   PubMed Web of Science ®Google Scholar
• Hassan M, Ansari J, Spooner D, et al. Chemotherapy for breast cancer (Review). Oncol Rep. 2010;24(5):1121–1131.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663–1671.
   PubMed Web of Science ®Google Scholar
• Yusuf R, Duan Z, Lamendola D, et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1–19.
   PubMed Web of Science ®Google Scholar
• Xu F, Wang F, Yang T, et al. Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell Int. 2014;14(1):142.
   PubMedGoogle Scholar
• Pryor DE, O'Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry. 2002;41(29):9109–9115.
   PubMed Web of Science ®Google Scholar
• Parker AL, Kavallaris M, McCarroll JA. Microtubules and their role in cellular stress in cancer. Front Oncol. 2014;4:153.
   PubMedGoogle Scholar
• Hari M, Wang Y, Veeraraghavan S, et al. Mutations in α- and β-tubulin that stabilize microtubules and confer resistance to colcemid and Vinblastine1. Mol Cancer Ther. 2003;2(7):597–605.
   PubMed Web of Science ®Google Scholar
• Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules . Mol Cancer Ther. 2006;5(2):270–278.
   PubMed Web of Science ®Google Scholar
• Checchi PM, Nettles JH, Zhou J, et al. Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci. 2003;24(7):361–365.
   PubMed Web of Science ®Google Scholar
• Yadav S, Verma PJ, Panda D. C-terminal region of MAP7 domain containing protein 3 (MAP7D3) promotes microtubule polymerization by binding at the C-terminal tail of tubulin. PLoS One. 2014;9(6):e99539.
   PubMed Web of Science ®Google Scholar
• Monroy BY, Sawyer DL, Ackermann BE, et al. Competition between microtubule-associated proteins directs motor transport. Nat Commun. 2018;9(1):1–12.
   PubMedGoogle Scholar
• Fu L, Fu H, Zhou L, et al. High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia. Sci Rep. 2016;6(1):1–9.
   PubMedGoogle Scholar
• Blum C, Graham A, Yousefzadeh M, et al. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II Colon cancer. Int J Oncol. 2008;33(3):579–584.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu X, Song L, et al. MAP7 promotes migration and invasion and progression of human cervical cancer through modulating the autophagy. Cancer Cell Int. 2020;20(1):1–8.
   PubMed Web of Science ®Google Scholar
• Comşa Ş, Cimpean AM, Raica M. The story of MCF-7 breast cancer cell line: 40 years of experience in research. Anticancer Res. 2015;35(6):3147–3154.
   PubMed Web of Science ®Google Scholar
• Gest C, Joimel U, Huang L, et al. Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines. BMC Cancer. 2013;13(1):63.
   PubMedGoogle Scholar
• Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50(18):6075–6086.
   PubMed Web of Science ®Google Scholar
• Chen S-Y, Hu S-S, Dong Q, et al. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo. Asian Pac J Cancer Prev. 2013;14(10):6135–6140.
   PubMedGoogle Scholar
• Liu S, Foulkes WD, Leung S, et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014;16(5):432.
   PubMed Web of Science ®Google Scholar
• Thelen A, Benckert C, Jonas S, et al. Liver resection for metastases from breast cancer. J Surg Oncol. 2008;97(1):25–29.
   PubMed Web of Science ®Google Scholar
• Markman M, Mekhail TM. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002;3(6):755–766.
   PubMedGoogle Scholar
• Cui H, Arnst K, Miller DD, et al. Recent advances in elucidating paclitaxel resistance mechanisms in non-small cell lung cancer and strategies to overcome drug resistance. Curr Med Chem. 2020;27(39):6573–6595.
   PubMed Web of Science ®Google Scholar
• Hooikaas PJ, Martin M, Mühlethaler T, et al. MAP7 family proteins regulate kinesin-1 recruitment and activation. J Cell Biol. 2019;218(4):1298–1318.
   PubMed Web of Science ®Google Scholar
• Boichuk S, Galembikova A, Sitenkov A, et al. Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance . Oncol Lett. 2017;14(4):5039–5045.
   PubMed Web of Science ®Google Scholar
• Komoto TT, Bernardes TM, Mesquita TB, et al. Chalcones repressed the AURKA and MDR proteins involved in metastasis and multiple drug resistance in breast cancer cell lines. Molecules. 2018;23(8):2018.
   PubMed Web of Science ®Google Scholar